Lundbeck Canada hails new national standard on psychological health and safety
in the workplace
TORONTO, Jan. 16, 2013 /CNW/ - Lundbeck Canada, a leading provider of
medications for treating mental illness, today expressed its strong support
for the new national standard on psychological health and safety in the
"Prevention is always the best way of reducing possible harm," said Patrick
Cashman, President of Lundbeck Canada. "Establishing this clear, tangible
approach to help Canada's employers better protect the mental health of their
team members is an extremely important and positive step forward."
The National Standard of Canada on Psychological Health and Safety in the
Workplace is voluntary, however it includes explicit requirements for
development of a psychological health and safety management plan, identifying
situations or processes which could present risks to psychological health, and
ensuring that employees are connected to services or resources to help deal
with mental illness.
"Steel-toed boots and other measures to protect the physical health of
employees are viewed as a given in Canadian workplaces; it's imperative that
mental and psychological health be viewed in an equally important way," said
"Better protecting the mental well-being of our country's workforce benefits
all Canadians through better productivity, lower health care costs and having
healthier, happier people driving our economy."
As a company dedicated to constantly improving the quality of lives of people
who live with mental illness, Lundbeck Canada has put measures in place aimed
at maintaining and improving the mental well-being of its employees. Flexible
work hours, the ability to work from home and an annual $500.00 benefit per
employee to direct towards any activity that contributes to psychological or
physical well-being (e.g. yoga classes, gym membership, photography classes)
are all offered to help Lundbeck Canada employees reduce stress and maintain
good mental health through an optimal work-life balance
ABOUT LUNDBECK CANADA
A division of the Denmark-based pharmaceutical maker H. Lundbeck A/S, Lundbeck
Canada Inc. has been a trusted source of innovative treatments for Canadians
since 1995 with headquarters in Montreal. Originally focused on providing
products for the treatment of depression, anxiety, Alzheimer's disease and
schizophrenia, Lundbeck Canada now offers cancer therapies for the treatment
of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Lundbeck's
Celexa® and Cipralex ® are two of the most widely used anti-depressants
prescribed by Canadian doctors. A patient-focused partner in Canadian health
care, Lundbeck Canada's mission is to improve the quality of life of people
suffering from Central Nervous System disorders and cancer.
Globally, Lundbeck was ranked #1 in a 2012 global survey by PatientView that
evaluated the ability of pharmaceutical companies to meet patient
expectations. In the survey, Lundbeck also took top honours in "best at
providing high-quality information to patients" and "best at being transparent
with external stakeholders".
Daniel McCarthy, Senior Director, External Relations Lundbeck Canada Inc.
email@example.com Phone (514) 501.6381
Ashley Curran, Senior Account Manager Veritas Communications
SOURCE: Lundbeck Canada Inc
To view this news release in HTML formatting, please use the following URL:
CO: Lundbeck Canada Inc
NI: HEA HEA
-0- Jan/16/2013 15:00 GMT
Press spacebar to pause and continue. Press esc to stop.